dreamcatcher
- 24 Aug 2012 22:54

http://www.medgenics.com/about_us.htm
Medgenics is developing a unique sustained-action therapeutic protein delivery technology for the treatment of a range of chronic diseases. The technology – called a “Biopump” – is made from the patient’s own skin and is implanted in a simple procedure to work inside the patient’s body, to produce and deliver the active protein steadily over a sustained period to treat the targeted disease. Medgenics believes that this biological approach can replace a major portion of the regular and costly injections of therapeutic proteins patients currently receive.
The Company has demonstrated proof-of-principle of its treatment procedure in a clinical trial using EPODURE in anemic patients. A long-acting version of EPODURE designed to produce and deliver a therapeutic dose of EPO steadily for six months or more began Phase I/II efficacy trials in Israel in mid-2008. Clinical trials with INFRADURE are intended follow in due course.
Beyond this, the Company plans to develop a pipeline of products based on its Biopump technology targeting the large and rapidly growing global $50+ billion protein therapy market, which is expected to grow to some $132 billion per year in 2013.
Medgenics is managed by a highly experienced team of biotechnology and biomedical device experts, and its Board of Directors and Scientific Advisory Board include highly experienced figures in the healthcare industry, in healthcare finance, as well as influential figures from the medical community and academia.
Share Price
Medgenics, Inc. commenced trading on the London Stock Exchange Alternative Investment Market (AIM), on Tuesday, 04 December 2007. The stock trades under two symbols: MEDG for Reg S shares and MEDU for unrestricted shares.

dreamcatcher
- 23 Oct 2013 15:06
- 28 of 38
Medgenics to present poster at ESGCT Congress
RNS
RNS Number : 2206R
Medgenics Inc
23 October 2013
Press Release
23 October 2013
Medgenics To Present Poster at European Society of Gene and Cell Therapy Congress to Highlight Results from Second-Generation Viral Vector
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that a poster highlighting the Company's second-generation EPODURE Biopump™ will be presented at the European Society of Gene and Cell Therapy Congress, taking place in Madrid October 25-28.
Posters will be showcased in Poster Reception Halls A-C November 1-3 and will be available for viewing from 9:30 a.m. to 2:30 p.m. local time. Poster presentations will take place from 10:00 a.m. to 12:00 p.m. The following Medgenics' poster will be presented during Poster Session B on Sunday, October 27:
· "Second generation EPODURE Biopump™ markedly extends duration of EPO delivery in mice, could prolong therapeutic effect in patients," by Miari, et. al. Poster Number P146.
EPODURE is an autologous dermal Biopump capable of the sustained production of therapeutic erythropoietin ("EPO") in the body using a small tissue explant from the patient's own skin and processed to continuously produce EPO. Each EPODURE Biopump is subsequently implanted subcutaneously into the patient aiming to provide continuous delivery of EPO.
About The European Society of Gene and Cell Therapy (ESGCT)
The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.
About Medgenics
Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia and hepatitis, among others. For more information, please visit www.medgenics.com.
Forward-looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.
dreamcatcher
- 28 Oct 2013 17:14
- 29 of 38
dreamcatcher
- 07 Nov 2013 16:52
- 30 of 38
Medgenics aims to use latest technology in trials in first half of 2014
By Giles Gwinnett November 07 2013, 3:01pm Viral vectors are used to deliver genetic material into cells and the Biopump delivers therapuetic proteins into patients using their own tissue to treat several chronic diseases, including anaemiaViral vectors are used to deliver genetic material into cells and the Biopump delivers therapuetic proteins into patients using their own tissue to treat several chronic diseases, including anaemia
Medgenics (LON:MEDG, NYSE:MDGN) plans to use its next generation of viral vectors in clinical trials beginning in the first half of next year.
It came as the biopharmaceutical firm, which is developing Biopump technology and recently appointed a new executive team, reported third quarter results.
Viral vectors are used to deliver genetic material into cells and the Biopump delivers therapeutic proteins into patients using their own tissue to treat several chronic diseases, including anaemia.
New president and chief executive Michael Cola said: "We are excited to be building upon the company's strong scientific and technological foundation, and are refining new strategic initiatives to advance the clinical development programme in carefully selected specialty and orphan indications."
New, positive data on the company's second-generation viral vectors were recently highlighted in a poster presentation at the European Society of Gene and Cell Therapy Congress in Madrid.
In vitro (ie, test tube) and in vivo (ie, living beings) models showed the potential to increase the duration and levels of the protein secretion of the Biopump along with enhanced surgical techniques.
"These advances can be clinically meaningful, particularly for patients on chronic protein therapy. Based on these results, we believe that all clinical programs, including the proposed EPODURE trial in the US, could benefit from the potentially improved performance from a second-generation vector," the company said.
For the nine months to September 30, Medgenics reported a net loss of US$11.92 million compared with a net loss of US$12.69 mln in 2012.
Gross R&D (research and development) expense for the first nine months of 2013 increased to US$6.56 million from US$5.13 mln in the same period of 2012 due to an increase in R&D personnel and clinical activities.
dreamcatcher
- 15 Nov 2013 15:21
- 31 of 38
Medgenics chairman buys $170,000 of shares
By Jamie Nimmo November 15 2013, 2:20pm Barer purchased 25,000 shares at an average price of $6.80 eachBarer purchased 25,000 shares at an average price of $6.80 each
Medgenics’ (LON:MEDG) chairman, Dr Sol Barer, has bought $170,000 worth of shares in the biopump developer.
Barer purchased 25,000 shares at an average price of $6.80 each. He now owns 72,000 shares or 0.4% of the company’s issued share capital.
The chairman also has the right to buy up to 1.3mln shares through options granted to him.
Last week, Medgenics unveiled plans to use its next generation of viral vectors in clinical trials beginning in the first half of next year.
Viral vectors are used to deliver genetic material into cells and the Biopump delivers therapeutic proteins into patients using their own tissue to treat several chronic diseases, including anaemia.
dreamcatcher
- 16 Nov 2013 21:23
- 32 of 38
dreamcatcher
- 03 Dec 2013 16:28
- 33 of 38
Medgenics chairman buys again, Oriel keen
By Philip Whiterow December 03 2013, 2:27pm Broker Oriel Securities today issued a buy recommendation with a 600p target price.
Medgenics' (LON:MEDG) chairman has bought his second sizeable chunk of shares in the drug delivery innovator in little over two weeks.
Dr Sol Barer bought 20,000 shares at US$6.589 at a total cost of around US$132,000. In November, Barer bought US$170,000 worth of stock in the Israeli group and with this latest purchase he now owns 92,000 shares or 0.5% directly. Adding in his options potentially increases his holding to 7.6%.
Medgenics has patented a novel delivery technology called Biopump and recently unveiled plans to use its next generation of viral vectors in clinical trials beginning in the first half of next year.
Viral vectors are used to deliver genetic material into cells and the Biopump delivers therapeutic proteins into patients using their own tissue to treat several chronic diseases, including anaemia.
Broker Oriel Securities today issued a buy recommendation with a 600p target price, adding that Biopump had the potential to revolutionise the production and delivery of protein based therapies.
Clinical data is due in 2014 from phase I/IIa trials in treating anaemia and hepatitis C, which should help to validate its clinical potential said the broker in a connected initiation note.
The technology is designed to overcome many of the drawbacks of regular, bolus injections of therapeutic proteins by using strips of a patients’ tissue so that the Biopumps secrete a steady stream of therapeutic protein into the body.
This replaces the need for frequent injections and in chronic conditions such as anaemia, diabetes, hepatitis and arthritis means lower cost, greater convenience, and fewer side effects.
Oriel said: “Although at a relatively early stage of development, Medgenics’ key risk lies in demonstrating the validity of the Biopumps’ delivery mechanism in a clinical setting.
“By using well characterised molecules, we believe the pharmaceutical risk is more in line with that of biosimilars.”
Shares rose 6% to 415p today.
dreamcatcher
- 16 Dec 2013 16:12
- 34 of 38
Still down 10% -
Purchase of Common Stock by Chairman
RNS
RNS Number : 6102V
Medgenics Inc
16 December 2013
Press Release
16 December 2013
Medgenics Reports Open Market Purchase of Common Stock by Chairman of the Board
Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), ("the Company"), the developer of BiopumpTM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on December 13, 2013, the Company was informed by Dr. Sol Barer, Medgenics' Chairman of the Board, that he purchased 20,000 shares of common stock on the open market on that day at an average price of $5.3711 per share.
Following this purchase, Dr. Barer now owns 112,000 shares of common stock, which represents approximately 0.6 per cent of the total issued shares of common stock. Dr. Barer, directly or through trusts for the benefit of Dr. Barer and his family, also has the right to purchase up to 1,315,000 shares of common stock pursuant to options previously granted (in aggregate Dr. Barer's shares of common stock and options represent 1,427,000 shares of common stock which represent approximately 7.7 per cent of the Company's total issued shares of common stock).
This announcement is being made pursuant to the London Stock Exchange's AIM Rules for Companies admitted to trading on the AIM market
dreamcatcher
- 18 Dec 2013 16:07
- 35 of 38
Purchase of Common Stock by Director
RNS
RNS Number : 8468V
Medgenics Inc
18 December 2013
Press Release
18 December 2013
Medgenics Reports Open Market Purchase of Common Stock by Director
Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), ("the Company"), the developer of BiopumpTM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that the Company was informed today by Dr. Alastair Clemow, a director of the Company, that he purchased 4,500 shares of common stock on the open market on 16 December at an average price of $5.7787 per share.
Following this purchase, Dr. Clemow now owns 18,500 shares of common stock, which represents approximately 0.1 per cent of the total issued shares of common stock. Dr. Clemow also has the right to purchase up to 105,714 shares of common stock pursuant to options previously granted (in aggregate Dr. Clemow's shares of common stock and options represent 124,214 shares of common stock which represent approximately 0.7 per cent of the Company's total issued shares of common stock).
This announcement is being made pursuant to the London Stock Exchange's AIM Rules for Companies admitted to trading on the AIM market.
dreamcatcher
- 05 Feb 2014 15:32
- 36 of 38
Up just under 16%
dreamcatcher
- 20 Feb 2014 21:17
- 37 of 38
Medgenics looks to accelerate gene therapy platform after transition year
By Giles Gwinnett
February 20 2014, 2:59pm
The company reported a net loss of US$17.13 million for the year ended December 31 last year compared with a net loss of $15.07 million in 2013
Medgenics (LON:MEDG, NYSE:MDGN) plans to accelerate its gene therapy platform and maximise the potential of its technology assets, it told investors, unveiling 2013 financial results.
The firm is developing Biopump to treat patients and last year repositioned itself as a rare and orphan disease firm with a brand new executive management team.
Michael Cola, president and chief exexcutive, told the statement: "2013 has been an important transition year for us as we build a foundation and corporate strategy to position the company for the future.
He said that based on results to date, the firm had developed a second generation viral vector and Biopump protocol that shows more durable protein production in mice - a model historically predictive of success in human clinical trials.
"We plan to utilise this new vector and protocol as we realign our research and development focus towards the orphan and rare disease market, where we feel the Biopump's attributes of continuous autologous protein/peptide production would be highly advantageous."
Cola said the company had two aims for 2014 - firstly to begin the Phase 1/2 EPODURE trial for human proof-of-concept of the Biopump platform with the second-generation viral vector and protocol, and to replicate the mouse results in humans.
Secondly, the company wants to obtain in-vitro (test tube) and in-vivo (living) preclinical data in human tummy-tuck tissue and mice in several rare and orphan disease indications.
The company reported a net loss of US$17.13 million for the year ended December 31 last year compared with a net loss of $15.07 million in 2012.
dreamcatcher
- 03 Mar 2014 20:33
- 38 of 38
Medgenics looks to exit AIM
By Ian Lyall
March 03 2014, 8:07am
The group which is developing a the Biopump for the sustained release of therapeutic proteins.
The group which is developing a the Biopump for the sustained release of therapeutic proteins.
The biotechnology group Medgenics (NYSE MKT:MDGN, LON:MEDG) has unveiled plans to cancel its AIM listing.
The group, which is developing a Biopump for the sustained release of therapeutic proteins, said the high cost of maintaining UK quote as well as limited trading volumes were two of the reasons for the proposed London exit.
Medgenics said it will maintain its quote on the NYSE MKT (formerly the AMEX).
A vote will be heard at the stockholder’s meeting on April 8. If the proposal is approved then the last day of trading on AIM would be April 15.
Medgenics said all stock on the UK share register will be added the US register.
It said either Capita Registrars or Corporate Stock Transfer, the company's US registrar, will send out transmittal letters to all stockholders whose shares were previously UK listed “providing them with further information regarding the transfer of their shares to the company's US share register